According to MassDevice.com, “Clearside Biomedical raised $14.4 million in a new round of equity financing, and said yesterday it enrolled the 1st patient in the Phase 3 Peachtree clinical trial of its CLS-TA for treating patients with macular edema associated with non-infectious uveitis.”  For more information on this transaction, please visit: http://www.massdevice.com/clearside-biomedical-raises-14-4-m-enrolls-1st-patient-in-phase-iii-trial/